Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 13Unknown 7Available 4Recruiting 2No longer available 2Active not recruiting 2Withdrawn 1Terminated 1Not yet recruiting 1Approved for marketing 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroendocrine Tumors 3Pheochromocytoma 1Paraganglioma 1Neuroblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Isotretinoin 3imetelstat 2Peripheral Blood Stem Cell Transplantation 2Cyclophosphamide 2thymoglobulin 1pazopanib 1naxitamab 1lorukafusp alfa 1liposomal doxorubicin 1keyhole-limpet hemocyanin 1fludarabine phosphate 1fludarabine 1defibrotide 1arginyllysine 1Whole-Body Irradiation 1Whole Body Imaging 1Vincristine 1Vaccines 1Tretinoin 1Topotecan 1Thiotepa 1Therapeutics 1Temozolomide 1Tacrolimus 1Stem Cell Transplantation 1Spermine Synthase 1Specimen Handling 1Radiotherapy 1Radiation 1Pentetic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Neuroblastoma × 3-Iodobenzylguanidine × Clear all
NCT00389766 2013-07-10

High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Withdrawn
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡